Randomized controlled trial of the lipid-lowering therapy with rosuvastatin and atorvastatin for the patients with coronary artery disease treated with percutaneous coronary intervention

Trial Profile

Randomized controlled trial of the lipid-lowering therapy with rosuvastatin and atorvastatin for the patients with coronary artery disease treated with percutaneous coronary intervention

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Atorvastatin (Primary) ; Rosuvastatin (Primary)
  • Indications Coronary artery disease
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Jul 2017 Status changed from recruiting to completed.
    • 30 Jul 2014 The dose for rosuvastatin has been increased from 2.5 mg/day to 5 mg/day, according to University Hospital Medical Information Network - Japan record.
    • 18 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top